Triumvira, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, has simultaneously submitted an IND to the U.S. Food and Drug... read more
Triumvira, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, has simultaneously submitted an IND to the U.S. Food and Drug... read more
Clinical-stage biopharmaceutical company, NextCure, has updated its filing for an IPO to raise up to $93 million. The company has applied to trade on NASDAQ under the symbol, "NXTC”.
... read more
AOBiome Featured in Bloomberg Businessweek
It was a snowy week in February 2009 when David Whitlock packed up... read more
Sirnaomics Inc. announced on 4/26/19 that it has sealed the C2 round of financing for $22 million. This round of funding was led by CR-CP Life Sciences Fund, a Hong Kong based joint venture... read more
Clinical-stage biopharma, Applied Therapeutics, updated the filing for its upcoming IPO. The company will raise up to $86 million. It intends to trade under the symbol, "APLT", on NASDAQ.
... read more